Objective      To determine the efficacy of levosimendan in patients with decompensated heart failure complicated with renal insufficiency.        Methods      Clinical data of 63 decompensated heart failure patients hospitalized in the department of cardiology from July 2013 to May 2015 were collected and retrospectively analyzed. These patients we

re divided into 2 groups according to the renal injury extent: L1 group [glomerular filtration rate (GFR): 15~60 mL/(min·1.73 m

2

)

n=33

]

and L2 group [GFR: 60~89 mL/(min·1.73 m

2

)

n=30

]

and all the patients were treated by infusion of levosimendan. N-terminal pro-B-type natriuretic peptide (NT-pro-BNP)

left ventricular ejection fraction (LVEF)

and GFR were compared and analyzed before treatment and on 1

3

7

and 30 d after treatment.       Results      Before treatment

there were no significant differences in the baseline data between the 2 groups except GFR (P0.05). On 1

3 and 7 d after treatment

NT-pro-BNP were significantly decreased in the 2 groups (P0.05)

and on 3 and 7 d after treatment

LVEF was significantly higher than the baseline value. Before and after treatment

NT-pro-BNP and LVEF showed no significant differences between the 2 groups (P0.05). On 1

3 and 7 d after treatment

GFR was significantly increased in the 2 groups (P0.05)

and on 30 d after treatment

GFR of group L1 was still increased (P0.05). After treatment

the level of △GFR (GFR change) was significantly higher in the L1 group than in the L2 group.       Conclusion      Levosimendan can improve heart and kidney functions in the patients with decompensated heart failure complicated with renal insufficiency

and the improvement of renal function is greater and longer in the patients with severe renal insufficiency.